Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Kim Oren Gradel, Thomas Stauffer Larsen, Henrik Frederiksen, Pernille Just Vinholt, Maria Iachina, Pedro Póvoa, Fernando Godinho Zampieri, Stig Lønberg Nielsen, Ram Benny Dessau, Jens Kjølseth Møller, Thøger Gorm Jensen, Ming Chen, John Eugenio Coia & Jelena Jelicic. (2022) Impact of C-reactive protein and albumin levels on short, medium, and long term mortality in patients with diffuse large B-cell lymphoma. Annals of Medicine 54:1, pages 713-722.
Read now
Read now
Jelena Jelicic, Thomas Stauffer Larsen, Henrik Frederiksen, Bosko Andjelic, Milos Maksimovic & Zoran Bukumiric. (2020) Statistical Challenges in Development of Prognostic Models in Diffuse Large B-Cell Lymphoma: Comparison Between Existing Models – A Systematic Review. Clinical Epidemiology 12, pages 537-555.
Read now
Read now
R. Andrew Harkins, Andres Chang, Sharvil P. Patel, Michelle J. Lee, Jordan S. Goldstein, Selin Merdan, Christopher R. Flowers & Jean L. Koff. (2019) Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma. Expert Review of Hematology 12:11, pages 959-973.
Read now
Read now
Articles from other publishers (15)
Jelena Jelicic, Karen Juul-Jensen, Zoran Bukumiric, Michael Roost Clausen, Ahmed Ludvigsen Al-Mashhadi, Robert Schou Pedersen, Christian Bjørn Poulsen, Peter Brown, Tarec Christoffer El-Galaly & Thomas Stauffer Larsen. (2023) Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models. Blood Cancer Journal 13:1.
Crossref
Crossref
Jinrong Zhao, Yan Zhang, Wei Wang, Wei Zhang & Dao-bin Zhou. (2022) Clinical Characteristics, Outcomes, and Risk Factors for Patients with Diffuse Large B-Cell Lymphoma and Development of Nomogram to Identify High-Risk Patients. Journal of Oncology 2022, pages 1-11.
Crossref
Crossref
N. George Mikhaeel, Martijn W. Heymans, Jakoba J. Eertink, Henrica C.W. de Vet, Ronald Boellaard, Ulrich Dührsen, Luca Ceriani, Christine Schmitz, Sanne E. Wiegers, Andreas Hüttmann, Pieternella J. Lugtenburg, Emanuele Zucca, Gerben J.C. Zwezerijnen, Otto S. Hoekstra, Josée M. Zijlstra & Sally F. Barrington. (2022) Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index. Journal of Clinical Oncology 40:21, pages 2352-2360.
Crossref
Crossref
Willem Daneels, Michael Rosskamp, Gilles Macq, Estabraq Ismael Saadoon, Anke De Geyndt, Fritz Offner & Hélène A. Poirel. (2022) Real-World Estimation of First- and Second-Line Treatments for Diffuse Large B-Cell Lymphoma Using Health Insurance Data: A Belgian Population-Based Study. Frontiers in Oncology 12.
Crossref
Crossref
Vicki A. Morrison, Laurie Hamilton, Augustina Ogbonnaya, Aditya Raju, Kristin Hennenfent & Aaron Galaznik. (2020) Treatment approaches for older and oldest patients with diffuse large B-cell lymphoma – Use of non-R-CHOP alternative therapies and impact of comorbidities on treatment choices and outcome: A Humedica database retrospective cohort analysis, 2007–2015. Journal of Geriatric Oncology 11:1, pages 41-54.
Crossref
Crossref
Vicki A. Morrison. 2020. Geriatric Oncology. Geriatric Oncology
583
612
.
Praveen Malayath. (2019) A Study of the Prognostic Significance of Serum Albumin Levels in Myelodysplastic Syndrome. Journal of Evidence Based Medicine and Healthcare 6:51, pages 3179-3183.
Crossref
Crossref
Kamil' Daniyalovich Kaplanov, N.P. Volkov, T.Yu. Klitochenko, I.V. Matveeva, A.L. Shipaeva, M.N. Shirokova, N.V. Davydova, E.G. Gemdzhian, D.S. Abramov, D.M. Konovalov, G.L. Snigur & N.A. Red'kina. (2019) Analysis Results of the Regional Registry of Patients with Diffuse Large B-cell Lymphoma: Risk Factors and Chemo-Immunotherapy Issues. Clinical oncohematology 12:2, pages 54-64.
Crossref
Crossref
Jelena Jelicic, Thomas Stauffer Larsen, Milos Maksimovic & Goran Trajkovic. (2019) Available prognostic models for risk stratification of diffuse large B cell lymphoma patients: a systematic review. Critical Reviews in Oncology/Hematology 133, pages 1-16.
Crossref
Crossref
Jorne L. BicclerSandra ElorantaPeter de Nully BrownHenrik FrederiksenMats JerkemanJudit JørgensenLasse Hjort JakobsenKarin E. SmedbyMartin BøgstedTarec C. El-Galaly. (2018) Optimizing Outcome Prediction in Diffuse Large B-Cell Lymphoma by Use of Machine Learning and Nationwide Lymphoma Registries: A Nordic Lymphoma Group Study. JCO Clinical Cancer Informatics:2, pages 1-13.
Crossref
Crossref
Vicki A. Morrison. 2018. Geriatric Oncology. Geriatric Oncology
1
31
.
Jorne Biccler, Sandra Eloranta, Peter de Nully Brown, Henrik Frederiksen, Mats Jerkeman, Karin E. Smedby, Martin Bøgsted & Tarec C. El-Galaly. (2018) Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI. Cancer Medicine 7:1, pages 114-122.
Crossref
Crossref
Monika PilichowskaStefania PittalugaJudith A. FerryJessica HemmingerHong ChangJennifer A. KanakryLaurie H. SehnTatyana FeldmanJeremy S. AbramsonAthena KritharisFrancisco J. Hernandez-IlizaliturriIzidore S. LossosOliver W. PressTimothy S. FenskeJonathan W. FriedbergJulie M. VoseKristie A. BlumDeepa JagadeeshBruce Woda, Gaurav K. GuptaRandy D. GascoyneElaine S. JaffeAndrew M. Evens. (2017) Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. Blood Advances 1:26, pages 2600-2609.
Crossref
Crossref
László Gulácsi, Valentin Brodszky, Petra Baji, Fanni Rencz & Márta Péntek. (2017) The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries. Advances in Therapy 34:5, pages 1128-1144.
Crossref
Crossref
Carlos Montalbán, Antonio Díaz-López, Ivan Dlouhy, Jordina Rovira, Armando Lopez-Guillermo, Sara Alonso, Alejandro Martín, Juan M. Sancho, Olga García, Jose M. Sánchez, Mario Rodríguez, Silvana Novelli, Antonio Salar, Antonio Gutiérrez, Maria J. Rodríguez-Salazar, Mariana Bastos, Juan F. Domínguez, Rubén Fernández, Sonia Gonzalez de Villambrosia, José A. Queizan, Raul Córdoba, Raquel de Oña, Andrés López-Hernandez, Julian M. Freue, Heidys Garrote, Lourdes López, Ana M. Martin-Moreno, Jose Rodriguez, Víctor Abraira & Juan F. García. (2017)
Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β
2
-microglobulin yields a more accurate GELTAMO-IPI
. British Journal of Haematology 176:6, pages 918-928.
Crossref
Crossref